PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS

1*1

Innovation, Sciences et

Office de la Propriété Intellectuelle du Canada

Canadian Intellectual Property Office

CA 3016410 A1 2017/09/21 (2D 3 016 410 (12) DEMANDE DE BREVET CANADIEN CANADIAN PATENT APPLICATION (13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2017/03/15

(87) Date publication PCT/PCT Publication Date: 2017/09/21

(85) Entrée phase nationale/National Entry: 2018/08/31

(86) N° demande PCT/PCT Application Νο.: EP 2017/056049

(87) N° publication PCT/PCT Publication No.: 2017/157972

(30) Priorités/Priorities: 2016/03/16 (US62/308.944);

(51) Cl.Int./Int.CI. C07K 7/06 (2006.01 ),

A61K 38/17 (2006.01 ), A61K 39/00 (2006.01 )

C07K 14/47 (2006.01), C07K 16/28 (2006.01) C07K7/08 (2006.01)

(71) Demandeur/Applicant:

(72) Inventeurs/lnventors:

MAHR, ANDREA, DE;

SCHOOR, OLIVER, DE;

WEINSCHENK, TONI, DE

2016/03/16 (GB1604458.8)

(74) Agent: GOWLING WLG (CANADA) LLP

(57) Abrégé/Abstract:

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate Τ cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

50 rue Victoria · Place du Portage 1 · Gatineau, (Québec) K1A0C9 · www.opic.ic.gc.ca

50 Victoria Street · Place du Portage 1 · Gatineau, Quebec K1A0C9 · www.cipo.ic.gc.ca

International Bureau

21 September 2017 (21.09.2017)

WIPOIPCT

(10) International Publication Number WO 2017/157972 Α1

(51) International Patent Classification:

C07K 7/06 (2006.01) C07K16/28 (2006.01)

Α61Κ 38/17 (2006.01) C07K 7/08 (2006.01)

Α61Κ39/00 (2006.01) C07K14/47 (2006.01)

PCT/EP2017/056049

15 March 2017 (15.03.2017)

(25) Filing Language: English

(26) Publication Language: English

1604458.8 16 March 2016 (16.03.2016) GB

62/308,944 16 March 2016 (16.03.2016) US

(71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH

[DE/DE]; Paul-Ehrlich-StraBe 15, 72076 Tübingen (DE).

(72) Inventors: MAHR, Andrea; Kirschenweg 22, 72076

Tübingen (DE). SCHOOR, Oliver; Eichhaldenstrasse 19,

72074 Tübingen (DE). WE IN SCHENK, Toni; hn Mor-

genrain 15, 73773 Aichwald (DE).

(74) Agent: KRAUB, Jan; BOEHMERT & BOEHMERT,

Pettenkoferstrasse 22, 80336 Munich (DE).

(81) Designated States(unless otherwise indicated, for every kind of national protection available)'. ΑΕ, AG, AL, AM, AO, AT, AU, ΑΖ, BA, ΒΒ, BG, ΒΗ, BN, BR, BW, BY, ΒΖ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, ΚΕ, KG, ΚΗ, ΚΝ, ΚΡ, KR, KW, ΚΖ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, ΜΚ, ΜΝ, MW, MX, MY, ΜΖ, NA, NG, NI, NO, ΝΖ, ΟΜ, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, ΤΜ, ΤΝ, TR, ΤΤ, ΤΖ, UA, UG, US, UZ, VC, VN, ΖΑ, ΖΜ, ZW.

(84) Designated States(unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, ΚΕ, LR, LS, MW, ΜΖ, NA, RW, SD, SL, ST, SZ, ΤΖ, UG, ΖΜ, ZW), Eurasian (AM, ΑΖ, BY, KG, ΚΖ, RU, TJ, ΤΜ), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(57) Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate Τ cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.